01228 CANBRIDGE-B
- 0.126
- -0.004-3.08%
CANBRIDGE-B News
CANbridge and Scriptr Global Announce Publication in the Journal Science Reporting the Discovery of the StitchR™ RNA Assembly Technology and its Application for the Treatment of Muscular Dystrophies
CANbridge Pharmaceuticals to Terminate Agreements to Downsize Operations in U.S.A
CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 40% But Its Business Prospects Need A Lift Too
BeiHai Kangcheng-B (01228): CAN103 for the treatment of Gaucher's Disease (GD) qualifies for priority review.
Beihai Kangcheng-B (01228) announced CAN103 (Vilapine β) for the treatment of Gaucher's disease (GD)...
Express News | CANbridge Pharmaceuticals Inc - Grant of Priority Review Status of Can103 for Treatment of Gaucher Disease
Beihai Kangcheng-B (01228.HK) appoints Fangxin Li as a non-executive director.
Grondragon September 30th |Beihai Kangcheng-B(01228.HK) announced that Fangxin Li has been appointed as a non-executive director and a member of the board of directors' remuneration committee, effective from September 30, 2024. The board of directors has also received the resignation letter of Hu Zhengguo as a non-executive director and a member of the board of directors' remuneration committee, effective from the date of effectiveness.
Express News | CANbridge Pharmaceuticals Inc - James Qun Xue Will Assume Interim Duties and Responsibilities of CFO
Express News | CANbridge Pharmaceuticals Inc - Glenn Hassan Has Tendered His Resignation as Chief Financial Officer
CANbridge Pharmaceuticals’ CAN103 for Gaucher Disease has been granted Priority Review Status by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).
Canbridge Pharmaceuticals Books Wider Attributable Loss in H1
CANBRIDGE-B: INTERIM REPORT 2024
Beijing Kanglecheng-B (01228.HK): Richard James Gregory appointed as a member of the audit committee.
On September 2, Geelong announced that due to Chen Kan's plan to spend more time on personal affairs, he has resigned as a non-executive director and a member of the audit committee, effective from September 2, 2024. After Chen Kan's resignation, independent non-executive director Richard James Gregory has been appointed as a member of the audit committee, effective from the effective date.
Beihai Kangcheng-B (01228.HK) has achieved significant growth in its mid-term performance, with a significant increase in research and development investment.
On August 30th, Gelonghui announced its interim performance. For the six months ended June 30, 2024, the group's revenue increased by CNY 1.7 million to CNY 44.8 million from CNY 43.1 million for the six months ended June 30, 2023. This is mainly due to the company's original plan to strategically focus on rare diseases in 2021, and the transition arrangement of Heidi An's distribution in Hong Kong will end in the second half of 2023. In addition to the sales in Hong Kong by Heidi An, the group's revenue increased by CNY 8.8 million or 24.4% compared to the same period in 2023, mainly due to Maier.
Express News | CANbridge Pharmaceuticals H1 Gross Profit RMB 29.4 Million
Express News | CANbridge Pharmaceuticals H1 Revenue RMB 44.8 Million
Express News | CANbridge Pharmaceuticals H1 Gross Margin 65.7%
Express News | CANbridge Pharmaceuticals H1 Adjusted Net Income RMB -242.5 Million
CANBRIDGE-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024
The expected interest rate cut by the U.S. Federal Reserve boosts the Hong Kong stock market, with real estate and golden industrial concept performing well.
①The expectation of a Fed rate cut is strengthening, which sectors are expected to benefit? ②Why did xpeng stock soar today?
Beihai Kangcheng-B (01228.HK) is planning to hold a board of directors meeting on August 29th to review its interim performance.
Bank of North China -B (01228.HK) announced on August 19 that the company will hold a board of directors meeting on Thursday, August 29, 2024 to consider and approve the unaudited mid-term performance of the company and its subsidiary for the six months ended June 30, 2024, including its release.
Analysis
Price Target
No Data
No Data